Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jan;45(1):80–85. doi: 10.1038/bjc.1982.10

Effects of endocrine therapy on steroid-receptor content of breast cancer.

R E Taylor, T J Powles, J Humphreys, R Bettelheim, M Dowsett, A J Casey, A M Neville, R C Coombes
PMCID: PMC2010955  PMID: 6277358

Abstract

In order to determine the mechanisms of relapse following response to endocrine therapy, we have measured the oestrogen receptor (RE) content of biopsies of breast cancer in patients receiving various types of endocrine treatment. RE content fell in responding (means of 260.2 to 12 fmol/mg protein) and in nonresponding (means of 155.1 to 31.8 fmol/mg protein) patients who had measurable receptor at the start of treatment. Some of these patients, and a further group of responders to endocrine therapy, were monitored until relapse. Tumour biopsies at the time of relapse showed that 10/14 tumour samples contained significant RE (mean of 86.7 fmol/mg protein; range less than 10-271 fmol/mg protein) after successful endocrine therapy. No relationship could be found between RE content and plasma gonadotrophin or steroid-hormone concentration, but the fall in RE content correlated with reduced numbers of tumour cells in the biopsy. These results indicate that relapse following successful endocrine therapy in breast cancer does not appear to be due to the emergence of RE-negative tumour cells. The fall in RE content during response to endocrine therapy may be due to reduced tumour-cell content of the biopsy.

Full text

PDF
85

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Barlock A., Huff K. K., Lippman M. E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer. 1980 Feb 15;45(4):792–794. doi: 10.1002/1097-0142(19800215)45:4<792::aid-cncr2820450430>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  2. Arafah B. M., Gullino P. M., Manni A., Pearson O. H. Effect of ovariectomy on hormone receptors and growth of N-nitrosomethylurea-induced mammary tumors in the rat. Cancer Res. 1980 Dec;40(12):4628–4630. [PubMed] [Google Scholar]
  3. Bodwin J. S., Clair T., Cho-Chung Y. S. Inverse relation between estrogen receptors and cyclic adenosine 3':5'-monophosphate-binding proteins in hormone-dependent mammary tumor regression due to dibutyryl cyclic adenosine 3':5'-monophosphate treatment or ovariectomy. Cancer Res. 1978 Oct;38(10):3410–3413. [PubMed] [Google Scholar]
  4. Cho-Chung Y. S., Bodwin J. S., Clair T. Cyclic AMP-binding proteins: inverse relationship with estrogen-receptors in hormone-dependent mammary tumor regression. Eur J Biochem. 1978 May;86(1):51–60. doi: 10.1111/j.1432-1033.1978.tb12283.x. [DOI] [PubMed] [Google Scholar]
  5. Coombes R. C., Dearnaley D., Humphreys J., Gazet J. C., Ford H. T., Nash A. G., Mashiter K., Powles T. J. Danazol treatment of advanced breast cancer. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1073–1076. [PubMed] [Google Scholar]
  6. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  7. Iqbal M. J., Johnson M. W. Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin. J Steroid Biochem. 1977 Sep;8(9):977–983. doi: 10.1016/0022-4731(77)90196-0. [DOI] [PubMed] [Google Scholar]
  8. Kiang D. T., Kennedy B. J. Factors affecting estrogen receptors in breast cancer. Cancer. 1977 Oct;40(4):1571–1576. doi: 10.1002/1097-0142(197710)40:4<1571::aid-cncr2820400429>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978 Dec;5(4):428–433. [PubMed] [Google Scholar]
  10. Namer M., Lalanne C., Baulieu E. E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980 May;40(5):1750–1752. [PubMed] [Google Scholar]
  11. Smith I. E., Fitzharris B. M., McKinna J. A., Fahmy D. R., Nash A. G., Neville A. M., Gazet J. C., Ford H. T., Powles T. J. Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet. 1978 Sep 23;2(8091):646–649. doi: 10.1016/s0140-6736(78)92759-9. [DOI] [PubMed] [Google Scholar]
  12. Sutherland R. L., Murphy L. C. The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer. 1980 Sep;16(9):1141–1148. doi: 10.1016/0014-2964(80)90172-3. [DOI] [PubMed] [Google Scholar]
  13. Webster D. J., Bronn D. G., Minton J. P. Estrogen receptor levels in multiple biopsies from patients with breast cancer. Am J Surg. 1978 Sep;136(3):337–338. doi: 10.1016/0002-9610(78)90289-1. [DOI] [PubMed] [Google Scholar]
  14. Wilkinson P., Ribeiro G., Adam H., Patterson J. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1980;5(2):109–111. doi: 10.1007/BF00435413. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES